Answers are grounded in this paper and cite their sources.
Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affecting over 10 million people worldwide, and is characterized by progressive dopaminergic neuron loss, α-synuclein aggregation, and disabling motor and non-motor symptoms for which current therapies offer only symptomatic relief. The identification of SNCA , LRRK2 , and related genes as drivers of both familial and sporadic PD has positioned RNA interference (RNAi), an endogenous gene-silencing mechanism, as a promising precision therapeutic strategy. This review provides an integrated synthesis of RNAi-based approaches for PD, spanning molecular mechanisms, rationale for targeting key PD-associated genes, recent preclinical evidence from animal and induced pluripotent stem cell (iPSC)-derived models, advances in central nervous system (CNS)-penetrant delivery systems, and the emerging role of microRNA (miRNA)-based modulation. We critically evaluate persistent translational barriers, including off-target effects, immunogenicity, and blood–brain barrier (BBB) penetration, and outline concrete future directions. As gene-silencing therapies move from the laboratory into early-phase clinical trials for PD, this review offers clinicians and researchers a timely, practical roadmap to understand how these treatments work, what challenges remain, and what to expect on the path toward clinical use.
No takes yet. Share an insight, caveat, or question.
Malekinejad et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: